Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial

<p><i>Background:</i> COV-BOOST is a multicentre, randomised, controlled, phase 2 trial of seven COVID-19 vaccines used as a third booster dose in June 2021. Monovalent messenger RNA (mRNA) COVID-19 vaccines were subsequently widely used for the third and fourth-dose vaccination ca...

Full description

Bibliographic Details
Main Authors:	Liu, X, Munro, APS, Wright, A, Feng, S, Janani, L, Aley, PK, Babbage, G, Baker, J, Baxter, D, Bawa, T, Bula, M, Cathie, K, Chatterjee, K, Dodd, K, Enever, Y, Fox, L, Qureshi, E, Goodman, AL, Green, CA, Haughney, J, Hicks, A, Jones, CE, Kanji, N, van der Klaauw, AA, Libri, V, Llewelyn, MJ, Mansfield, R, Maallah, M, McGregor, AC, Minassian, AM, Moore, P, Mughal, M, Mujadidi, YF, Belhadef, HT, Holliday, K, Osanlou, O, Osanlou, R, Owens, DR, Pacurar, M, Palfreeman, A, Pan, D, Rampling, T, Regan, K, Saich, S, Saralaya, D, Sharma, S, Sheridan, R, Stokes, M, Thomson, EC, Todd, S, Lambe, T, Snape, MD
Other Authors:	COV-BOOST study group
Format:	Journal article
Language:	English
Published:	Elsevier 2023

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial

Similar Items